Efficacy of aliskiren, compared with angiotensin ii blockade, in slowing the progression of diabetic nephropathy in db/db mice: Should the combination therapy be a focus?

American Journal of Translational Research

Volumn 7, Issue 5, 2015, Pages 825-840

  Zhou, Guangyu ^a,b   Liu, Xia ^b   Cheung, Alfred K ^b,c   Huang, Yufeng ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Albuminuria; Angiotensin converting enzyme inhibitor (ACEI); Angiotensin II receptor blocker (ARB); Direct renin inhibitor (DRI); Podocyte; Renal fibrosis

Indexed keywords

ALBUMIN; ALDOSTERONE; ALISKIREN; B7 ANTIGEN; COLLAGEN TYPE 4; DESMIN; ENALAPRIL; FIBRONECTIN; HEMOGLOBIN A1C; MALONALDEHYDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEPHRIN; P47PHOX PROTEIN; PEPTIDES AND PROTEINS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PODOCIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; RENIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VALSARTAN; WILMS TUMOR PROTEIN 1;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFICACY; GLOMERULOSCLEROSIS; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY FIBROSIS; KIDNEY FUNCTION; MALE; MOUSE; NEPHRITIS; NONHUMAN; OXIDATIVE STRESS; PODOCYTE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; RNA ISOLATION; SYSTOLIC BLOOD PRESSURE; URINALYSIS; WESTERN BLOTTING;

MUS;

EID: 84936752828     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. [1] Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collab orative Study Group. N Engl J Med 1993; 329: 1456-1462.
2. [2] Morgan T, Anderson A, Bertram D, MacInnis RJ. Effect of candesartan and lisinopril alone and in combination on blood pressure and mi-croalbuminuria. J Renin Angiotensin Aldoste-rone Syst 2004; 5: 64-71.
3. [3] Forclaz A, Maillard M, Nussberger J, Brunner HR, Burnier M. Angiotensin II receptor blockade: is there truly a beneft of adding an ACE inhibitor? Hypertension 2003; 41: 31-36.
4. [4] Doulton TW. ACE inhibitor-angiotensin receptor blocker combinations: a clinician’s perspective. Mini Rev Med Chem 2006; 6: 491-497.
5. [5] Azizi M, Bissery A, Lamarre-Cliche M, Menard J. Integrating drug pharmacokinetics for phe-notyping individual renin response to angioten-sin II blockade in humans. Hypertension 2004; 43: 785-790.
6. [6] Kramer BK, Ritthaler T, Schweda F, Ittner KP, Scholz H, Riegger GA and Kurtz A. Effects of the angiotensin II type-1 receptor antagonist ZD7155 on angiotensin II-mediated regulation of renin secretion and renal renin gene expression, renal vasoconstriction, and blood pressure in rats. J Cardiovasc Pharmacol 1998; 31: 700-705.
7. [7] Jensen C, Herold P, Brunner HR. Aliskiren: the frst renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008; 7: 399-410.
8. [8] Komers R. Renin inhibition in the treatment of diabetic kidney disease. Clin Sci (Lond) 2013; 124: 553-566.
9. [9] Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, Meiners S, Feldman DL, Webb RL, Garrelds IM, Jan Danser AH, Luft FC and Muller DN. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005; 46: 569-576.
10. [10] Lu H, Rateri DL, Feldman DL, Jr RJ, Fukamizu A, Ishida J, Oesterling EG, Cassis LA and Daugh-erty A. Renin inhibition reduces hypercholes-terolemia-induced atherosclerosis in mice. J Clin Invest 2008; 118: 984-993.
11. [11] Huang Y, Border WA, Yu L, Zhang J, Lawrence DA and Noble NA. A PAI-1 Mutant, PAI-1R, Slows Progression of Diabetic Nephropathy. J Am Soc Nephrol 2008; 19: 329-338.
12. [12] Peters H, Border WA, Noble NA. Targeting TGF-beta overexpression in renal disease: maximizing the antifbrotic action of angiotensin II blockade. Kidney Int 1998; 54: 1570-1580.
13. [13] Gu C, Zhou G, Noble NA, Border WA, Cheung AK and Huang Y. Targeting reduction of pro-teinuria in glomerulonephritis: Maximizing the antifbrotic effect of valsartan by protecting podocytes. J Renin Angiotensin Aldosterone Syst 2012; 15: 177-189.
14. [14] Zhou G, Cheung AK, Liu X, Huang Y. Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury and renal oxidative stress and inflammation. Clin Sci (Lond) 2014; 126: 707-720.
15. [15] Zhang J, Gu C, Lawrence DA, Cheung AK, Huang Y. A PAI-1 mutant retards diabetic ne-phropathy in db/db mice through protecting podocytes. Exp Physiol 2014; 99: 802-815.
16. [16] Shankland SJ. The podocyte’s response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69: 2131-2147.
17. [17] Ziyadeh FN, Wolf G. Pathogenesis of the podo-cytopathy and proteinuria in diabetic glomeru-lopathy. Curr Diabetes Rev 2008; 4: 39-45.
18. [18] Yu D, Petermann A, Kunter U, Rong S, Shank-land SJ and Floege J. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol 2005; 16: 1733-1741.
19. [19] Sanden SK, Wiggins JE, Goyal M, Riggs LK, Wiggins RC. Evaluation of a thick and thin section method for estimation of podocyte number, glomerular volume, and glomerular volume per podocyte in rat kidney with Wilms’ tumor-1 protein used as a podocyte nuclear marker. J Am Soc Nephrol 2003; 14: 2484-2493.
20. [20] Guo JK, Menke AL, Gubler MC, Clarke AR, Harrison D, Hammes A, Hastie ND and Schedl A. WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. Hum Mol Genet 2002; 11: 651-659.
21. [21] Reiser J, von Gersdorff G, Loos M, Oh J, Asa-numa K, Giardino L, Rastaldi MP, Calcaresi N, Watanabe H, Schwarz K, Faul C, Kretzler M, Davidson A, Sugimoto H, Kalluri R, Sharpe AH, Kreidberg JA, Mundel P. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004; 113: 1390-1397.
22. [22] Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond) 2013; 124: 139-152.
23. [23] Tojo A, Asaba K, Onozato ML. Suppressing renal NADPH oxidase to treat diabetic nephropa-thy. Expert Opin Ther Targets 2007; 11: 1011-1018.
24. [24] Xu M, Dai DZ, Dai Y. Normalizing NADPH oxi-dase contributes to attenuating diabetic ne-phropathy by the dual endothelin receptor antagonist CPU0213 in rats. Am J Nephrol 2009; 29: 252-256.
25. [25] Kang YS LM, Song HK, Hyun YY, Cha JJ, Ko GJ, Kim SH, Lee JE, Han JY, Cha DR. Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice. Nephrol Dial Transplant 2011; 26: 1194-1204.
26. [26] Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DN, Feldt S, Cumin F, Ma-niara W, Persohn E, Schuetz H, Jan Danser AH and Nguyen G. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008; 52: 130-136.
27. [27] Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE. Aliskiren, a novel renin inhibitor, is renoprotec-tive in a model of advanced diabetic nephropa-thy in rats. Diabetologia 2007; 50: 2398-2404.
28. [28] Fraune C, Lange S, Krebs C, Holzel A, Baucke J, Divac N, Schwedhelm E, Streichert T, Velden J, Garrelds IM, Danser AH, Frenay AR, van Goor H, Jankowski V, Stahl R, Nguyen G and Wenzel UO. AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease. Am J Physiol Renal Physiol 2012; 303: F1037-1048.
29. [29] Gross O, Girgert R, Rubel D, Temme J, Theissen S and Muller GA. Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fbrosis. Am J Hypertens 2011; 24: 355-361.
30. [30] Sakuraya K, Endo A, Someya T, Hirano D, Mu-rano Y, Fujinaga S, Ohtomo Y and Shimizu T. The synergistic effect of mizoribine and a direct Renin inhibitor, aliskiren, on unilateral ure-teral obstruction induced renal fbrosis in rats. J Urol 2014; 191: 1139-1146.
31. [31] Parving HH, Persson F, Lewis JB, Lewis EJ, Hol-lenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446.
32. [32] Persson F, Lewis JB, Lewis EJ, Rossing P, Hol-lenberg NK and Parving HH. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care 2010; 33: 2304-2309.
33. [33] Li SY, Chen YT, Yang WC, Tarng DC, Lin CC, Yang CY and Liu WS. Effect of add-on direct re-nin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease. BMC Nephrol 2012; 13: 89.
34. [34] Dong YF, Liu L, Lai ZF, Yamamoto E, Kataoka K, Nakamura T, Fukuda M, Tokutomi Y, Nako H, Ogawa H and Kim-Mitsuyama S. Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. J Hyper-tens 2010; 28: 1554-1565.
35. [35] Gandhi S, Srinivasan BP, Akarte AS. Effective blockade of RAAS by combination of aliskiren and olmesartan improves glucose homeosta-sis, glomerular fltration rate along with renal variables in streptozotocin induced diabetic rats. Eur J Pharm Sci 2012; 46: 32-42.
36. [36] Wu WP, Chang CH, Chiu YT, Ku CL, Wen MC, Shu KH and Wu MJ. A reduction of unilateral ureteral obstruction-induced renal fbrosis by a therapy combining valsartan with aliskiren. Am J Physiol Renal Physiol 2010; 299: F929-941.
37. [37] Yamamoto E, Kataoka K, Dong YF, Nakamura T, Fukuda M, Tokutomi Y, Matsuba S, Nako H, Nakagata N, Kaneko T, Ogawa H and Kim-Mit-suyama S. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension 2009; 54: 633-638.
38. [38] Lu H, Balakrishnan A, Howatt DA, Wu C, Charni-go R, Liau G, Cassis LA and Daugherty A. Comparative effects of different modes of renin angiotensin system inhibition on hypercholes-terolaemia-induced atherosclerosis. Br J Pharmacol 2012; 165: 2000-2008.
39. [39] Huang Y, Border WA, Noble NA. Functional re-nin receptors in renal mesangial cells. Curr Hy-pertens Rep 2007; 9: 133-139.
40. [40] Nguyen G, Danser AH. Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. Exp Physiol 2008; 93: 557-563.
41. [41] Batenburg WW, Danser AH. (Pro)renin and its receptors: pathophysiological implications. Clin Sci (Lond) 2012; 123: 121-133.
42. [42] Harel Z, Gilbert C, Wald R, Bell C, Perl J, Juur-link D, Beyene J and Shah PS. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ 2012; 344: e42.
43. [43] Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Pie-gas LS, Svendsen TL, Teo KK and Yusuf S. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ON-TARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553.